Chan Alexander, Tsourkas Andrew
Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
BME Front. 2024 Jan 25;5:0035. doi: 10.34133/bmef.0035. eCollection 2024.
Protein biologics are powerful therapeutic agents with diverse inhibitory and enzymatic functions. However, their clinical use has been limited to extracellular applications due to their inability to cross plasma membranes. Overcoming this physiological barrier would unlock the potential of protein drugs for the treatment of many intractable diseases. In this review, we highlight progress made toward achieving cytosolic delivery of recombinant proteins. We start by first considering intracellular protein delivery as a drug modality compared to existing Food and Drug Administration-approved drug modalities. Then, we summarize strategies that have been reported to achieve protein internalization. These techniques can be broadly classified into 3 categories: physical methods, direct protein engineering, and nanocarrier-mediated delivery. Finally, we highlight existing challenges for cytosolic protein delivery and offer an outlook for future advances.
Biochem Pharmacol. 2017-4-10
Lab Chip. 2013-10-7
J Control Release. 2021-5-10
AAPS PharmSciTech. 2023-10-19
Indian J Ophthalmol. 2023-6
Pharm Nanotechnol. 2024
Trends Biotechnol. 2025-6-9
ACS Bio Med Chem Au. 2025-2-27
ACS Biomater Sci Eng. 2025-3-10
Front Mol Neurosci. 2024-12-11
Nat Cancer. 2023-8
Mol Ther. 2023-8-2
Immunooncol Technol. 2023-3-9
ACS Appl Mater Interfaces. 2023-5-10